<\/p>\n
The Problem.<\/strong> Chronic low back pain is one of the leading causes of disability globally, affecting approximately 600 million people<\/a>. Those afflicted often find themselves at an impasse in therapy, as traditional relief focuses primarily on \u00a0NSAIDs\u00a0 and physical exercise without offering substantial improvement.<\/p>\n <\/p>\n The challenge arises when patients turn to more potent analgesics when over-the-counter medications like \u00a0ibuprofen\u00a0 fail. This reliance on stronger options contributes significantly to the \u00a0dependence\u00a0 issues plaguing society today.<\/p>\n <\/p>\n What Is It?<\/strong> Importantly, we are not discussing the act of smoking cannabis. \u00a0Ver-01\u00a0 is a highly standardized pharmaceutical product that is a \u00a0‘complete spectrum extract’\u00a0 derived from a patented strain of \u00a0Cannabis sativa\u00a0 known as \u00a0DKJ127\u00a0.<\/p>\n <\/p>\n But what does ‘complete spectrum’ entail? This term signifies that, alongside the primary psychoactive component, \u00a0THC\u00a0, the extract incorporates a diverse range of other plant compounds. These include various cannabinoids<\/a> (like \u00a0Cannabigerol\u00a0 and \u00a0Cannabidiol\u00a0), \u00a0terpenes\u00a0, and \u00a0flavonoids\u00a0. This intricate composition may be vital for its efficacy and tolerability profile.<\/p>\n <\/p>\n Methodology.<\/strong> There has long been considerable trepidation surrounding cannabis, largely attributed to the historical emphasis on its harmful effects. However, with the necessity for therapeutic alternatives, a team of researchers evaluated the effectiveness of \u00a0Ver-01\u00a0 in a Phase 3 clinical trial\u2014the final stage before a drug can be commercialized.<\/p>\n <\/p>\n
![\"A](\"https:\/\/teknomers.com\/en\/wp-content\/uploads\/2025\/10\/1759365255_186_In-the-competition-to-be-the-top-remedy-for-back.jpeg\"\/)
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n